IRIS
TOSCA, ELENA MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.893
AS - Asia 1.260
EU - Europa 966
SA - Sud America 307
AF - Africa 50
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 2
Totale 4.487
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.841
CN - Cina 418
SG - Singapore 322
IT - Italia 249
BR - Brasile 227
VN - Vietnam 211
IE - Irlanda 186
RU - Federazione Russa 162
HK - Hong Kong 131
DE - Germania 86
FR - Francia 74
FI - Finlandia 41
GB - Regno Unito 41
IN - India 36
ZA - Sudafrica 31
AR - Argentina 27
MX - Messico 22
JP - Giappone 20
SE - Svezia 20
CA - Canada 18
NL - Olanda 18
ES - Italia 17
PL - Polonia 16
CO - Colombia 15
IQ - Iraq 15
BD - Bangladesh 14
AT - Austria 11
EC - Ecuador 11
IR - Iran 10
CL - Cile 9
ID - Indonesia 9
TR - Turchia 9
BE - Belgio 8
CZ - Repubblica Ceca 8
MY - Malesia 8
VE - Venezuela 7
AU - Australia 6
DO - Repubblica Dominicana 6
PK - Pakistan 6
SA - Arabia Saudita 6
JO - Giordania 5
UA - Ucraina 5
AE - Emirati Arabi Uniti 4
ET - Etiopia 4
LT - Lituania 4
PH - Filippine 4
PS - Palestinian Territory 4
UZ - Uzbekistan 4
AL - Albania 3
CH - Svizzera 3
KE - Kenya 3
LK - Sri Lanka 3
NZ - Nuova Zelanda 3
PE - Perù 3
TN - Tunisia 3
TW - Taiwan 3
UY - Uruguay 3
AZ - Azerbaigian 2
BO - Bolivia 2
CR - Costa Rica 2
HU - Ungheria 2
IL - Israele 2
KR - Corea 2
KZ - Kazakistan 2
LB - Libano 2
LV - Lettonia 2
MA - Marocco 2
PY - Paraguay 2
QA - Qatar 2
RO - Romania 2
SI - Slovenia 2
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BY - Bielorussia 1
DM - Dominica 1
DZ - Algeria 1
EG - Egitto 1
EU - Europa 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
GW - Guinea-Bissau 1
GY - Guiana 1
HR - Croazia 1
LA - Repubblica Popolare Democratica del Laos 1
LC - Santa Lucia 1
LU - Lussemburgo 1
MN - Mongolia 1
MU - Mauritius 1
NG - Nigeria 1
NO - Norvegia 1
NP - Nepal 1
OM - Oman 1
SN - Senegal 1
UG - Uganda 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.487
Salva come PNG Salva come JPEG
Città #
Dallas 297
San Jose 220
Ashburn 191
Dublin 186
Singapore 166
Chandler 148
Hong Kong 124
Beijing 113
Ho Chi Minh City 92
Boardman 78
Los Angeles 73
Pavia 72
Council Bluffs 63
Lauterbourg 47
New York 47
Hanoi 43
Shanghai 41
Moscow 38
Munich 36
Nanjing 32
Redondo Beach 32
Johannesburg 31
São Paulo 28
Milan 27
Buffalo 26
Lawrence 26
Medford 26
Princeton 26
Helsinki 20
Wilmington 20
Turku 18
Dearborn 17
Jacksonville 17
Shenyang 17
Florence 16
Santa Clara 16
Hebei 15
Nanchang 15
Orem 15
Warsaw 15
Tokyo 14
Brooklyn 12
Atlanta 10
Da Nang 10
Guangzhou 10
Rome 10
Stockholm 10
Tianjin 10
Changsha 9
Frankfurt am Main 9
Nuremberg 9
Ann Arbor 8
Chennai 8
Denver 8
Houston 8
Jiaxing 8
Mexico City 8
Montreal 8
Paris 8
Rio de Janeiro 8
Washington 8
Brussels 7
Chicago 7
Eindhoven 7
London 7
Poplar 7
Brescia 6
Düsseldorf 6
Hyderabad 6
Medellín 6
Mira 6
Porto Alegre 6
San Francisco 6
Seattle 6
Boston 5
Bắc Ninh 5
Fortaleza 5
Girifalco 5
Heemskerk 5
Kunming 5
Phoenix 5
Pittsburgh 5
Tehran 5
Addis Ababa 4
Amsterdam 4
Ankara 4
Baghdad 4
Biên Hòa 4
Bogotá 4
Brasília 4
Bắc Giang 4
Cagliari 4
Can Tho 4
Caracas 4
Castano Primo 4
Dhaka 4
Fairfield 4
Falkenstein 4
Genoa 4
Guayaquil 4
Totale 2.919
Salva come PNG Salva come JPEG
Nome #
Quantitative evaluation of RC-106 antitumor activity in GBM spheroids through tumor growth inhibition modeling based on cell counts data 176
Methods and tools for multiscale modelling in Systems Pharmacology: a review 133
Dynamic energy budget based models of tumor-in-host growth inhibition and cachexia onset in preclinical settings. 121
Artificial intelligence and machine learning: just a hype or a new opportunity for pharmacometrics? 120
Leveraging Two-Stage delta Global Sensitivity Analysis method to inform parameter estimation in PBPK models 119
Evaluation of software tools for Bayesian estimation on population models:an update based on current software versions 117
A PK/PD model for tumor-in-host growth kinetics following administration of an antiangiogenic agent given alone or in combination regimens 113
Translating Preclinical Insights into Clinical Outcomes: A Predictive Framework for Overall response rate and time to progression in Solid Tumors 104
An integrated pipeline for evaluating antitumor efficacy of RC-106 on glioblastoma spheroids 103
Modeling tumor growth inhibition and toxicity outcome after administration of anticancer agents in xenograft mice: A Dynamic Energy Budget (DEB) approach 103
Cancer Cachexia: A Dynamic Energy Budget ({DEB})-Based Model for Tumor-Related Anorexia and Sarcopenia 101
Dealing with stochasticity in precision dosing decision-making processes by fully exploiting PK-PD modelling in Reinforcement Learning algorithms. A practical case-study on Vancomycin continuous infusion in ICU patients 100
Model-based analysis of patient-derived organoids for evaluating anticancer drugs 98
A Dynamic Energy Budget (DEB) based modeling framework to describe tumor-in-host growth inhibition and cachexia onset during anticancer treatment in in vivo xenograft studies 98
Evaluation of a PK/PD DEB-based model for tumor-in-host growth kinetics under anticancer treatment 94
Application of Artificial Neural Networks to Predict the Intrinsic Solubility of Drug-Like Molecules 93
A genetic algorithm for covariate selection 93
In vitro– in vivo correlation (Ivivc) population modeling for the in silico bioequivalence of a long‐acting release formulation of progesterone 92
In vitro-in vivo correlation (IVIVC) population modeling for the in silico bioequivalence of a long-acting release formulation of Progesterone 90
A Population Dynamic Energy Budget-Based Tumor Growth Inhibition Model for Etoposide Effects on Wistar Rats 90
Facing the limits of the genetic algorithms for covariate selection 88
Combining Reinforcement Learning and PK-PD models to personalize multiple drug administration: an application to Axitinib-Anti-Hypertensive treatment in metastatic renal cancer patients 87
A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib 86
Modeling approaches for reducing safety-related attrition in drug discovery and development: a review on myelotoxicity, immunotoxicity, cardiovascular toxicity, and liver toxicity 85
Development of a genetic algorithm for covariate analysis in population pharmacokinetic models 85
Evaluation of a tumor growth inhibition (TGI) model integrating dynamic energy budget (DEB) theory 84
Dynamic Energy Budget (DEB) based models of tumor-in-host growth inhibition and cachexia onset 82
A tumor-in-host DEB-based approach for modeling cachexia and bevacizumab resistance 81
Modeling tumor growth inhibition in Glioblastoma spheroids after exposure to RC-106, a novel sigma receptors modulator 78
A Two-Stages Global Sensitivity Analysis by using the delta sensitivity index in presence of correlated inputs: Application on a Tumor Growth Inhibition model based on the Dynamic Energy Budget theory 77
A tumor-in-host Dynamic Energy Budget (DEB)-based paradigm for preclinical to clinical translation: predictions of tumor-in-host growth dynamics 76
Predicting tumor volume doubling time and progression-free survival curves in cancer patients from patient-derived-xenograft (PDX) models: a translational model-based population approach 72
How Modelling and Simulations combined with Artificial Intelligence can improve Precision Dosing 72
Modeling resistance development to Bevacizumab in xenograft experiments by coupling hypoxia-mediated mechanism and a Dynamic Energy Budget (DEB) based tumor-in-host model 72
Integrating Reinforcement Learning and PK-PD modelling to enable precision dosing: a multi-objective optimization for the treatment of Polycithemia Vera patients with Givinostat 70
A Two-Stages Global Sensitivity Analysis in presence of correlated inputs: Application on a Tumor-in-host-growth Inhibition model based on the Dynamic Energy Budget theory 70
Precision dosing by integrating Reinforcement Learning and PK-PD models: application to givinostat treatment of Polycythemia Vera 70
mvLognCorrEst: an R package for sampling from multivariate lognormal distributions and estimating correlations from uncomplete correlation matrix 68
In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients 67
PopPK-PD modelling of Carboplatin-induced myelosuppression to support therapeutic drug monitoring and dose individualization in cancer patients using Electronic Health Record Data 67
Reduced food-intake and sarcopenia in animal models of cancer anorexia-cachexia syndrome: a Dynamic Energy Budget (DEB)-based modeling approach 66
Predicting tumor dynamics in treated patients from patient-derived-xenograft mouse models: a translational model-based approach 65
Model-informed reinforcement learning for enabling precision dosing via adaptive dosing 65
PKPD modelling of MEN1611 anti-tumor effect in xenograft models to predict efficacy threshold concentrations in HER2-positive advanced or metastatic breast cancer patient population 64
Replacement, Reduction, and Refinement of Animal Experiments in Anticancer Drug Development: The Contribution of 3D In Vitro Cancer Models in the Drug Efficacy Assessment 63
Go beyond the limits of genetic algorithm in daily covariate selection practice 62
Predicting ADMET properties from molecule SMILE: a bottom-up approach using attention-based Graph Neural Networks 60
A clinical trial simulator to predict the effect of an adaptive dosing regimen of an investigated compound on platelets, white blood cells and haematocrit in patients with Polycythemia Vera 59
Precision Dosing in Presence of Multiobjective Therapies by Integrating Reinforcement Learning and PK-PD Models: Application to Givinostat Treatment of Polycythemia Vera 58
Staggered Herringbone Microfluid Device for the Manufacturing of Chitosan/TPP Nanoparticles: Systematic Optimization and Preliminary Biological Evaluation 57
Model-based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2-positive advanced or metastatic breast cancer patients 56
Translational modeling of tumor response to treatment: bridging preclinical to clinical studies 56
Reinforcement Learning and PK-PD Models Integration to Personalize the Adaptive Dosing Protocol of Erdafitinib in Patients with Metastatic Urothelial Carcinoma 50
Predicting Tumor Volume Doubling Time and Progression-Free Survival in Untreated Patients from Patient-Derived-Xenograft (PDX) Models: A Translational Model-Based Approach 46
Modeling restoration of gefitinib efficacy by co-administration of MET inhibitors in an EGFR inhibitor-resistant NSCLC xenograft model: A tumor-in-host DEB-based approach 39
Impact of sampling procedure on individual pharmacokinetic parameter estimation methods 36
Totale 4.597
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.722
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.722
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211 0 0 0 0 0 0 0 0 0 0 0 1
2021/2022151 2 2 10 0 4 4 7 27 10 5 18 62
2022/2023440 48 41 6 27 25 36 2 30 199 1 9 16
2023/2024303 27 62 15 14 25 54 18 20 6 16 8 38
2024/2025901 18 97 35 35 43 11 43 44 220 49 103 203
2025/20262.547 191 252 344 410 340 78 340 103 217 161 72 39
Totale 4.597